107. J Oncol Pharm Pract. 2018 Jan 1:1078155218761798. doi: 10.1177/1078155218761798. [Epub ahead of print]Verapamil as a culprit of palbociclib toxicity.Gowarty JL(1), Herrington JD(1).Author information: (1)Scott and White Medical Center-Temple, Temple, TX, USA.A promising drug, palbociclib, received accelerated approval as a first linetreatment when used with the aromatase inhibitor, letrozole, for postmenopausalwomen with hormone receptor positive advanced or metastatic breast cancer. Wereport a case of a patient who presented with febrile neutropenia, grade 3stomatitis with lip swelling, periorbital edema, and transaminitis while onpalbociclib and verapamil. Labs normalized upon discontinuation of verapamil and our patient was able to continue treatment with palbociclib and letrozole.Verapamil's inhibition of both permeability-glycoprotein (P-gp) and CYP3A4 issuspected to have led to the adverse side effects seen in our patient.DOI: 10.1177/1078155218761798 PMID: 29523051 